Description

This comprehensive lecture explores current and emerging biologic therapies for discogenic low back pain. The speaker discusses the inflammatory mechanisms behind disc degeneration and reviews both allogeneic and autologous treatments, including PRP, bone marrow concentrate, and adipose-derived biologics. Key findings from clinical studies highlight the importance of platelet concentration and suggest comparable efficacy between PRP and BMAC. Regulatory challenges surrounding allogeneic therapies and SVF are addressed, along with promising developments in exosome research. The presentation emphasizes the need for standardized protocols and large-scale RCTs to define optimal treatment strategies and regulatory pathways in regenerative spinal therapies.